Fish Oil Supplementation in Lactation

NCT ID: NCT00266305

Last Updated: 2008-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

1998-12-31

Study Completion Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of the study was to examine whether fish oil supplementation of lactating mothers affect infant development during first year of life, focusing on visual and mental development. A follow-up studies are conducted in order to see if early intake of long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFA) have any long-term effects on health, primarily immun function and markers of cardiovascular risk.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:

Studies indicate that infants, who are fed formula without n-3 LCPUFA, have slower visual development than those, who receive n-3 LCPUFA in breast-milk. The mental development seems also to depend on whether infants are breast-fed or not. Long-term health has also been proposed to be affected (The infant origin of adult disease hypothesis). It is not clear whether these differences is due to dietary LCPUFA as comparison of breast-fed and formula-fed infants are complicated by the socio-demographic differences that exist between mother, who choose to breast-feed or not. Recent studies indicate that LCPUFA supplementation of formulas has beneficial effects on the visual acuity and mental abilities of infants. The LCPUFA content of breast-milk varies and this could potentially be of importance for infant development.

Methods:

211 pregnant women with a high (\>80 percentile) or low (\< mean) fish intake were recruited. After birth mother with low fish intake were randomized to receive 4 g/day of fish oil or olive oil for the first 4 months of the lactation period. 150 mother-infant pairs were followed for 1 year gathering information on maternal n-3 LCPUFA intake and infant development (growth, developmental milestones, visual acuity, cognitive functions and language acquisition). Milk samples were collected at 0, 2, 4 and 9 months and blood samples were taken from the mother and the infant at 4 months of age in order to determine the biochemical effect of the supplementation.

The children were followed-up at 2½ years of age and around 7 years of age. The study is performed in association to the National Birth Cohort.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Development and Health

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

n-3 LCPUFA Infant development Visual acuity Immune function Breast milk

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fish oil

Group Type EXPERIMENTAL

Fish oil (Dry n-3, BASF)

Intervention Type BEHAVIORAL

5 g/oil daily for the first four month of lactation

Olive oil

Control group

Group Type PLACEBO_COMPARATOR

Fish oil (Dry n-3, BASF)

Intervention Type BEHAVIORAL

5 g/oil daily for the first four month of lactation

High fish

Reference group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fish oil (Dry n-3, BASF)

5 g/oil daily for the first four month of lactation

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women with uncomplicated singleton pregnancy
* No metabolic disorders and prepregnancy BMI \< 30 kg/m2
* Intention to exclusively breast-feed for 4 mo
* Fish intake below the Danish mean or above 80th percentile (reference group)

Exclusion Criteria

* Pre- or post term delivery (\< 37 or \> 43 wks of gestation)
* Abnormal weight for gestation (outside 10th-90th percentile range)
* Apgar score 5 min after delivery \< 8
* Infant admission to a neonatal department
* If supplementation did not begin within 2 wks after delivery
Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Danish Research Agency

OTHER

Sponsor Role collaborator

BASF

INDUSTRY

Sponsor Role collaborator

Technical University of Denmark

OTHER

Sponsor Role collaborator

University of Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dept. of Human Nutrition, University of Copenhagen

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lotte Lauritzen, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Department of Human Nutrition, Royal Veterinary and Agricultural University, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Human Nutrition

Frederiksberg, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Lauritzen L, Jorgensen MH, Mikkelsen TB, Skovgaard lM, Straarup EM, Olsen SF, Hoy CE, Michaelsen KF. Maternal fish oil supplementation in lactation: effect on visual acuity and n-3 fatty acid content of infant erythrocytes. Lipids. 2004 Mar;39(3):195-206. doi: 10.1007/s11745-004-1220-8.

Reference Type RESULT
PMID: 15233397 (View on PubMed)

Lauritzen L, Hoppe C, Straarup EM, Michaelsen KF. Maternal fish oil supplementation in lactation and growth during the first 2.5 years of life. Pediatr Res. 2005 Aug;58(2):235-42. doi: 10.1203/01.PDR.0000169978.92437.58. Epub 2005 Jul 8.

Reference Type RESULT
PMID: 16006428 (View on PubMed)

Hoppe C, Udam TR, Lauritzen L, Molgaard C, Juul A, Michaelsen KF. Animal protein intake, serum insulin-like growth factor I, and growth in healthy 2.5-y-old Danish children. Am J Clin Nutr. 2004 Aug;80(2):447-52. doi: 10.1093/ajcn/80.2.447.

Reference Type RESULT
PMID: 15277169 (View on PubMed)

Ulbak J, Lauritzen L, Hansen HS, Michaelsen KF. Diet and blood pressure in 2.5-y-old Danish children. Am J Clin Nutr. 2004 Jun;79(6):1095-102. doi: 10.1093/ajcn/79.6.1095.

Reference Type RESULT
PMID: 15159241 (View on PubMed)

Lauritzen L, Kjaer TM, Fruekilde MB, Michaelsen KF, Frokiaer H. Fish oil supplementation of lactating mothers affects cytokine production in 2 1/2-year-old children. Lipids. 2005 Jul;40(7):669-76. doi: 10.1007/s11745-005-1429-6.

Reference Type RESULT
PMID: 16196417 (View on PubMed)

Lauritzen L, Jorgensen MH, Olsen SF, Straarup EM, Michaelsen KF. Maternal fish oil supplementation in lactation: effect on developmental outcome in breast-fed infants. Reprod Nutr Dev. 2005 Sep-Oct;45(5):535-47. doi: 10.1051/rnd:2005044.

Reference Type RESULT
PMID: 16188206 (View on PubMed)

Larnkjaer A, Christensen JH, Michaelsen KF, Lauritzen L. Maternal fish oil supplementation during lactation does not affect blood pressure, pulse wave velocity, or heart rate variability in 2.5-y-old children. J Nutr. 2006 Jun;136(6):1539-44. doi: 10.1093/jn/136.6.1539.

Reference Type RESULT
PMID: 16702318 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FØTEK 2: 93s-2468-å96-00020

Identifier Type: -

Identifier Source: secondary_id

FØTEK 3: 2011-00-0028

Identifier Type: -

Identifier Source: secondary_id

KF 01-300/98

Identifier Type: -

Identifier Source: secondary_id

KF 01-183/01

Identifier Type: -

Identifier Source: secondary_id

KVL-IHE-D72

Identifier Type: -

Identifier Source: org_study_id